{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:10:24Z","timestamp":1792746624593,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.eururo.2024.01.017","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T13:55:32Z","timestamp":1710424532000},"page":"95-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Prostate Cancers in the Prostate-specific Antigen Interval of 1.8\u20133 ng\/ml: Results from the G\u00f6teborg-2 Prostate Cancer Screening Trial"],"prefix":"10.1016","volume":"86","author":[{"given":"Fredrik","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wallstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hugosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Arnsrud Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.01.017_b0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.01.017_b0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of followup in the G\u00f6teborg Randomized Population-Based Prostate Cancer Screening Trial","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"J Urol"},{"issue":"22","key":"10.1016\/j.eururo.2024.01.017_b0015","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.01.017_b0020","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.01.017_b0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.01.017_b0030","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.01.017_b0035","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.01.017_b0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/21681805.2021.1881612","article-title":"The G\u00d6TEBORG Prostate Cancer Screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate","volume":"55","author":"Kohestani","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2024.01.017_b0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2015.12.006","article-title":"Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the G\u00f6teborg Randomised Screening Trial","volume":"70","author":"Grenabo Bergdahl","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.01.017_b0050","doi-asserted-by":"crossref","first-page":"e048144","DOI":"10.1136\/bmjopen-2020-048144","article-title":"ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI","volume":"11","author":"Marsden","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2024.01.017_b0055","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","article-title":"Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study","volume":"7","author":"Eldred-Evans","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.01.017_b0060","doi-asserted-by":"crossref","first-page":"e059482","DOI":"10.1136\/bmjopen-2021-059482","article-title":"Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial","volume":"12","author":"Nam","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2024.01.017_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4521","article-title":"Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study","volume":"341","author":"Vickers","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.01.017_b0070","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.01.017_b0075","doi-asserted-by":"crossref","first-page":"djv095","DOI":"10.1093\/jnci\/djv095","article-title":"Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study","volume":"107","author":"Bryant","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.01.017_b0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","article-title":"An evaluation of screening pathways using a combination of magnetic resonance imaging and prostate-specific antigen: results from the IP1-PROSTAGRAM study","volume":"6","author":"Eldred-Evans","year":"2023","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:21:42Z","timestamp":1722532902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0302283824000526"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.01.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancers in the Prostate-specific Antigen Interval of 1.8\u20133 ng\/ml: Results from the G\u00f6teborg-2 Prostate Cancer Screening Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}